Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Organovo stock

Own Organovo stock in just a few minutes.

Organovo Holdings, Inc is a diagnostics & research business based in the US. Organovo shares (ONVO) are listed on the NASDAQ and all prices are listed in US Dollars. Organovo employs 7 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Organovo

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ONVO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Organovo share price

Use our graph to track the performance of ONVO stocks over time.

Organovo shares at a glance

Information last updated 2021-04-23.
52-week range$6.02 - $23.92
50-day moving average $9.89
200-day moving average $11.04
Wall St. target price$3.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.21

Buy Organovo shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Organovo stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Organovo financials

Gross profit TTM $-3,416,000
Return on assets TTM -26.93%
Return on equity TTM -68.21%
Profit margin 0%
Book value $2.92
Market capitalisation $68.4 million

TTM: trailing 12 months

Shorting Organovo shares

There are currently 444,132 Organovo shares held short by investors – that's known as Organovo's "short interest". This figure is 3.8% down from 461,618 last month.

There are a few different ways that this level of interest in shorting Organovo shares can be evaluated.

Organovo's "short interest ratio" (SIR)

Organovo's "short interest ratio" (SIR) is the quantity of Organovo shares currently shorted divided by the average quantity of Organovo shares traded daily (recently around 233753.68421053). Organovo's SIR currently stands at 1.9. In other words for every 100,000 Organovo shares traded daily on the market, roughly 1900 shares are currently held short.

However Organovo's short interest can also be evaluated against the total number of Organovo shares, or, against the total number of tradable Organovo shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Organovo's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Organovo shares in existence, roughly 60 shares are currently held short) or 0.0784% of the tradable shares (for every 100,000 tradable Organovo shares, roughly 78 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Organovo.

Find out more about how you can short Organovo stock.

Organovo share dividends

We're not expecting Organovo to pay a dividend over the next 12 months.

Have Organovo's shares ever split?

Organovo's shares were split on a 1:20 basis on 18 August 2020. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Organovo shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Organovo shares which in turn could have impacted Organovo's share price.

Organovo share price volatility

Over the last 12 months, Organovo's shares have ranged in value from as little as $6.018 up to $23.92. A popular way to gauge a stock's volatility is its "beta".

ONVO.US volatility(beta: 0.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organovo's is 0.7226. This would suggest that Organovo's shares are less volatile than average (for this exchange).

Organovo overview

Organovo Holdings, Inc. , a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site